Eli Lilly and Company (NYSE:LLY) had its price objective increased by stock analysts at Leerink Swann from $92.00 to $93.00 in a report released on Monday. The firm presently has a “market perform” rating on the stock. Leerink Swann’s target price indicates a potential upside of 6.61% from the stock’s current price.

Other research analysts also recently issued reports about the company. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a report on Wednesday, July 26th. BMO Capital Markets reiterated a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reiterated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank reiterated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $89.12.

Shares of Eli Lilly and (NYSE LLY) traded up 0.71% during midday trading on Monday, hitting $87.85. The company had a trading volume of 2,503,815 shares. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $89.09. The firm’s 50-day moving average is $84.38 and its 200-day moving average is $82.29. The firm has a market capitalization of $92.68 billion, a P/E ratio of 38.01 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.86 earnings per share. On average, analysts predict that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/23/eli-lilly-and-company-lly-given-new-93-00-price-target-at-leerink-swann.html.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 990,000 shares of company stock valued at $82,949,650. Insiders own 0.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and in the second quarter valued at approximately $129,000. Heritage Trust Co acquired a new stake in shares of Eli Lilly and in the first quarter valued at approximately $135,000. Finally, Point72 Asia Hong Kong Ltd lifted its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. 75.53% of the stock is owned by institutional investors.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.